Meet the Team Behind Carver Biosciences
Walter Strapps
Co-Founder and CEO
Co-Founder and CEO
|
Dr. Walter R. Strapps is the Co-founder and CEO of Carver Biosciences, Inc. Prior to taking the leadership role at Carver, he was Chief Scientific Officer at Gemini Therapeutics where he led all aspects of pre-clinical research, PK and biomarkers for Gemini’s clinical trials. Before joining Gemini, Dr. Strapps was Vice President of Discovery at Intellia Therapeutics, leading programs across a range of therapeutic areas. Dr. Strapps held previous roles in RNA Therapeutics at Merck & Co., Inc in Pennsylvania and California and at Sirna Therapeutics and Sentigen Biosciences in Colorado and New York respectively. Dr. Strapps obtained his doctorate, M.A. and M.Phil. degrees from Columbia University and B.Sc. from McGill University. Dr. Strapps serves on the board of Sona Nanotech. Walter was born and raised in Nova Scotia and is a proud Bluenoser.
|
Shape Divider - Style waves
Cameron Myhrvold
Co-Founder and Assistant Professor
Co-Founder and Assistant Professor
|
Cameron Myhrvold is an Assistant Professor of Molecular Biology at Princeton University. His work specializes in the development of CRISPR-based technologies for studying RNA, with an emphasis on detecting and destroying RNA viruses. He received a PhD in Systems Biology from Harvard in 2016. His PhD studies in synthetic biology and nucleic acid nanotechnology, supported by a Fannie and John Hertz Foundation fellowship, involved the development of three technologies that demonstrated a variety of applications for self-assembled nanostructures. During his postdoc, he turned his attention towards the RNA-targeting CRISPR effector protein Cas13, where he has led or co-led the development of four Cas13-based technologies, including CARMEN, CARVER, and SHINE.
Dr. Myhrvold is the Chairman of Carver's Scientific Advisory Board. |
Forbes 30 Under 30, 2019
STAT Wunderkind, 2020 |
Shape Divider - Style waves
Nessan Bermingham
Advisor – Khosla Ventures
Advisor – Khosla Ventures
|
Nessan Bermingham is Executive Chairman of Triplet Therapeutics, Inc. He is a serial biotech entrepreneur and investor who has founded several companies including Triplet, Korro Bio and Intellia Therapeutics, “one of the top 10 biotech start-ups in 2014” and a “Fierce 15 biotech company,” taking the company from concept to IPO and large partnering deals with approximately 200 employees. He has nearly two decades of experience in Life Sciences startups and investments, including small molecules, biologics, medical devices, and diagnostics through venture, public, and secondary markets. As a venture partner at Atlas Venture and managing partner at Omega Funds, he successfully invested in and managed multiple investments across the United States and Europe. Currently he is also a venture partner at Atlas Venture and is Chairman of the Board of Directors of F-star and Akrevia Therapeutics. He served as Intellia’s President and CEO from inception until December 2017. Previously he was an independent advisory board member of the California Institute of Regenerative Medicine (CIRM) and MerckSerono KGaA. He received his Ph.D. in Molecular Biology from Imperial College London and was a Howard Hughes Associate Fellow at Baylor College of Medicine. He is an avid mountain biker, snowboarder and trail runner.
|